Open access
Jul 2026
A post-marketing surveillance study of a human rabies vaccine in China (2020–2024)
Yisheng Jun’an® rabies vaccine exhibits a favorable safety profile with mild-to-moderate reactions, support its use in post-exposure prophylaxis, supporting its use in post-exposure prophylaxis.
Zhijie Cui, Lianfu Wang, Zhiyuan Ran et al.
· Frontiers in Public Health · 0 citations